Enjoying several expert talks by key metabolism researchers, including the talented @SezSaysScience as part of the @UQMedicine supported Mini-symposium on #metabolism.
Congratulations to the amazing researchers awarded @FightMND funding to support much needed research into improving our understanding of #MND. Thank you to every donor that made this possible.
Enjoying quiet time in the lab as @melkg97@StephanieHowe98 and @AmberGreen67157 take on the challenge of not speaking for 48hrs to support those who have lost their voices to #ALS#MND. Click below to support a worthy cause����@MNDFoundation @UQMedicine
https://t.co/ai8CeKXB6S?
We will be extending abstract submission until CoB Tuesday 26th September for those of you running a bit tight to the deadline!
https://t.co/8jCHrGxrha
Very grateful for an opportunity to learn from an amazing lineup of delegates across the Asia-Pacific regions at the 2023 @pactals meeting. Looking forward to building better research connections
In, this #OpenAccess manuscript by the talented EMCR @StephanieHowe98 et al., we explored associations between #Ghrelinand#LEAP2 (endocrine factors and regulators of #appetite) in ALS; findings were somewhat unexpected. A thread to help explain (1 of 5) https://t.co/DvoT8273xC
4/5 – #PALS with higher #ghrelin were more likely to have lower #BMI & #FatMass, suggesting they were at greater risk of #malnutrition. They also had greater risk of earlier death; are benefits of ghrelin lost, and can we target this to improve outcomes? More research 🔬needed.
3/5 – When comparing findings with functional decline, lower #ghrelin and greater #LEAP2ghrelin was associated with lower physical capacity; #ghrelin does more than regulate appetite. It can be neuroprotective 🧠 and support muscle 💪 function. Are these benefits lost in #ALS?
2/5 - Seeking to improve understanding of why some #PALS lose appetite, we show that postprandial hunger hormone #ghrelin is lower in ALS, and a big increase in #LEAP2ghrelin, suggesting #LEAP2 might block #ghrelin actions. @ZigmanLab was instrumental in making sense of this.
Abstracts are open for the Aus/NZ #MND Research Symposium 2023 in beautiful Wollongong 17-18 November. Talks will be selected from abstracts, lots of options available for #EMCRs@mndaustralia@FightMND@MNDNSW@UOW@wollongong_nsw
Pls RT https://t.co/dwQlZNvY86
Hi Network, we are recruiting!!!!
Research Fellow and Research Assistant.
If you want to be part of a dynamic team who plays with genetics, develops cell/zebrafish models of human diseases and conducts drug discovery campaigns! You should have a look 👇 1/3
Please share 🙏
@FightMND@Fred_Steyn@HoldomCory Excited to have the very talented #EMCR@HoldomCory join the discussion as he provides insights into his recent manuscript; if interested, you can find a copy here - https://t.co/OC4HDuiZfs
Our Scientific Seminar Series is back with a new time on Tues, Feb 28 at 12pm AEDT! Our first talk is @Fred_Steyn & @HoldomCory from @Steyn_Lab with 'Use and validation of digital technologies, including actigraphy, for care and research in MND.' For more https://t.co/Ui88w4IKN5
I'm excited to share our paper following from @rpavaneijk's work on the use of passive actigraphy for monitoring #ALS#MND function outside the clinic. There is clearly a lot of opportunity to expand the potential of this technology. @Steyn_Lab@Ngo_Lab:
https://t.co/0nI4vnkaR8
I'm excited to share our paper following from @rpavaneijk's work on the use of passive actigraphy for monitoring #ALS#MND function outside the clinic. There is clearly a lot of opportunity to expand the potential of this technology. @Steyn_Lab@Ngo_Lab:
https://t.co/0nI4vnkaR8
Does hypothalamus size matter in #ALS? Patients with low hypothalamic volume with low BMI tend to lose fat mass and have increased risk for earlier death. Thank you to the #PALS and their friends and family who contributed to this work. https://t.co/dpwQ5N0MYY🧠@EANeurology (1/4)